ADAR Antibody
Product Sizes
50ul
£264.00
OAAN03739-50UL
100ul
£379.00
OAAN03739-100UL
200ul
£581.00
OAAN03739-200UL
About this Product
- SKU:
- OAAN03739
- Additional Names:
- DSH; AGS6; G1P1; IFI4; P136; ADAR1; DRADA; DSRAD; IFI-4; K88DSRBP
- Clonality:
- Polyclonal
- Extra Details:
- Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP); neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site; but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV); vesicular stomatitis virus (VSV); measles virus (MV); hepatitis delta virus (HDV); and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV; MV; VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV); editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV; VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W; thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However; high levels of ADAR1 inhibit HDV replication.
- Gene Details:
- adenosine deaminase; RNA specific
- Host:
- Rabbit
- Immunogen:
- Recombinant Protein
- Isotype:
- IgG
- Molecular Weight:
- 136 kDa
- Protein Details:
- Proprotein convertase subtilisin/kexin type 9
- Purification:
- Affinity purification
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- Store at +4C. For long term storage; aliquote and store at -20C. Avoid freeze/thaw cycles.
- Supplier:
- Aviva Systems Biology
- Type:
- Antibodies: Polyclonal Antibody
- Manufacturer's Data Sheet:html_datasheet.php
